Xeris Built Momentum Through Q2, but Recorlev's Second Half Will Define the Year

Xeris Biopharma Holdings (XERS) reports Q2 2026 earnings before market open on August 6, 2026, with analysts expecting the specialty pharmaceutical company to deliver $0.02 per share on revenue of approximately $90.13 million. The central question: can XERS sustain its recent profitability momentum after posting its first positive quarter in Q1, or will investors see a return to the volatility that has characterized its earnings history? With the stock trading at $8.11 and analysts maintaining a bullish stance, this report will test whether the company's transition from development-stage losses to consistent profitability is real.

Part 1: Earnings Preview

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative formulations of established molecules, with key products including Gvoke (glucagon injection) for severe hypoglycemia, Keveyis for periodic paralysis, and Recorlev for Cushing's syndrome. The company has transitioned from a development-stage biotech to a commercial-stage operation generating meaningful revenue.

XERS will report Q2 2026 results before market open on August 6, with the consensus calling for EPS of $0.02 on revenue of $90.13 million. The most recent quarter (Q1 2026) delivered actual EPS of $0.01, marking a significant milestone as the company's first profitable quarter. Compared to the year-ago quarter (Q2 2025), when XERS reported -$0.01 per share, the consensus estimate represents a +300% year-over-year improvement and would mark the second consecutive profitable quarter.

Three key themes define this earnings story:

Revenue Growth Trajectory: With Q2 revenue estimated at $90.13 million versus $67.71 million in the year-ago quarter, investors are watching whether XERS can sustain the 26-36% revenue growth trajectory that has characterized recent quarters. The company's full-year 2026 guidance of $380-390 million (issued in May) suggests management expects continued momentum across its commercial portfolio.

Profitability Sustainability: After years of losses, XERS posted its first profitable quarter in Q1 2026. The critical question is whether this marks an inflection point or a one-time event. Analysts project accelerating profitability through 2027, with full-year 2027 EPS estimates of $0.33 representing +175% growth from 2026's expected $0.12.

Commercial Execution: The company's ability to drive adoption of its key products—particularly Gvoke in the diabetes market and Recorlev in the rare disease space—will determine whether the revenue growth story remains intact. Any commentary on market share gains, prescription trends, or payer coverage will be closely scrutinized.

Analyst sentiment remains constructive heading into the print. The consensus has held steady at $0.02 for Q2 over the past 90 days, though estimates have been revised down slightly from $0.05 three months ago. For the full year, the $0.12 consensus has remained unchanged, suggesting analysts are confident in the company's ability to deliver on its profitability targets despite the modest Q2 estimate reduction.

Part 2: Historical Earnings Performance

XERS has demonstrated inconsistent earnings performance over the past four quarters, with a pattern of both significant beats and notable misses that reflects the company's transition from unprofitable to profitable operations.

The most recent quarter (Q1 2026) delivered a massive surprise, with actual EPS of $0.01 versus an estimate of $0.00—though the percentage surprise calculation is distorted by the near-zero estimate. More meaningfully, this marked the company's first profitable quarter. Prior to that, Q4 2025 produced a strong +100% beat ($0.06 actual vs. $0.03 estimate), demonstrating operational leverage as revenue scaled. However, Q3 2025 saw a -100% miss ($0.00 actual vs. $0.01 estimate), and Q2 2025 delivered a +66.67% beat (-$0.01 actual vs. -$0.03 estimate).

The pattern reveals a company in transition: the two most recent quarters have been profitable and beat estimates, while the prior two quarters showed the volatility typical of a company approaching breakeven. The trend is clearly positive—moving from losses to profits—but the magnitude of surprises (both positive and negative) suggests earnings remain difficult to forecast precisely. Investors should expect continued volatility in estimate accuracy even as the directional trend improves.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

XERS reports before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

XERS has exhibited significant volatility around earnings events, with an average absolute Day 0 move of 8.38% and an average Day 0 range of 15.98%—both well above typical small-cap biotech volatility. The most dramatic reaction came in Q2 2025 (August 2025), when the stock surged 20.22% on Day 0 following a better-than-expected loss, with an intraday range of nearly 18%. More recent reports have been calmer: the May 2026 Q1 report produced a 4.08% Day 0 gain, while the March 2026 Q4 report saw a modest -1.63% decline despite a significant earnings beat.

The Day +1 follow-through has been more muted, averaging 3.08% with a 6.27% range, suggesting most of the price discovery happens in the immediate reaction. Notably, positive Day 0 moves have sometimes reversed on Day +1 (as in May 2026), while other times they've extended (as in August 2025). The takeaway: investors should expect a high-single-digit percentage move on the day of the report, with the potential for double-digit swings if results deviate significantly from expectations.

Part 2.2: Options Market Expected Move

The options market is pricing a 9.54% expected move (±$0.77, range $7.34-$8.88) through the August 21 expiration, which is slightly above the historical average Day 0 move of 8.38% but well below the average Day 0 range of 15.98%. This suggests options traders are anticipating a meaningful but not extreme reaction—consistent with recent earnings volatility rather than the explosive moves seen in mid-2025. The 88.05% implied volatility reflects elevated uncertainty, though the expected move implies the market is pricing in a more moderate outcome than the stock's most volatile historical prints.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on XERS heading into earnings, with a consensus rating of 4.50 out of 5.00—firmly in Buy territory. The analyst community consists of 6 Strong Buys, 0 Moderate Buys, 2 Holds, and 0 Sells, reflecting broad confidence in the company's commercial trajectory and profitability inflection.

The average price target of $11.29 implies 39% upside from the current price of $8.11, with a wide range of targets from a low of $8.00 (essentially flat to current levels) to a high of $18.00 (122% upside). This dispersion reflects differing views on how quickly XERS can scale profitability and whether the current valuation adequately reflects the company's transition from development-stage losses to sustainable earnings.

Sentiment has remained unchanged over the past month, with the Strong Buy count, Hold count, and average recommendation all holding steady at 6, 2, and 4.50 respectively. This stability suggests analysts are waiting for the Q2 print to validate their bullish thesis rather than making preemptive adjustments. The lack of recent downgrades despite the stock's run from $5.25 (52-week low) to current levels indicates conviction in the growth story, though the presence of two Hold ratings suggests some caution about valuation at current levels.

Part 4: Technical Picture

XERS enters earnings with a 72% Buy signal from the Barchart Technical Opinion, unchanged from both one week and one month ago, indicating stable technical momentum heading into the report. The stock is trading at $8.11, positioned above its 50-day ($7.57), 100-day ($6.78), and 200-day ($7.07) moving averages, confirming an intact longer-term uptrend. However, the stock is trading below its shorter-term 5-day ($8.19), 10-day ($8.25), and 20-day ($8.39) moving averages, suggesting recent consolidation or pullback from near-term highs.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not overwhelming, consistent with the recent pullback from short-term moving averages
• Medium-term (100% Buy): Strong buy signal across the intermediate timeframe reflects the stock's sustained advance above key moving averages and confirms the primary trend remains bullish
• Long-term (50% Buy): Moderate buy signal in the longer-term view suggests the overall trend is constructive but not at extreme bullish levels

Trend Characteristics: The technical environment shows Average strength with a Weakening direction, suggesting momentum is intact but losing steam heading into the earnings event—a setup that could produce outsized moves if results surprise in either direction.

The technical setup presents a neutral-to-slightly-cautious picture for earnings. While the stock maintains its position above all major long-term moving averages (a bullish structural signal), the recent pullback below short-term averages and the "Weakening" directional characteristic suggest momentum has stalled. The $8.39 level (20-day MA) represents immediate resistance, while the $7.57 level (50-day MA) provides nearby support. Given the stock's tendency to produce 8-10% moves on earnings and the current consolidation pattern, XERS appears coiled for a directional break—with the medium-term 100% Buy signal suggesting any pullback may be viewed as a buying opportunity by technically-oriented investors. The key will be whether results can reignite the momentum that carried the stock from its $5.25 low to recent highs near $10.